AU2019246719B2 - A triple pharmaceutical combination comprising dabrafenib, trametinib and an Erk inhibitor - Google Patents

A triple pharmaceutical combination comprising dabrafenib, trametinib and an Erk inhibitor Download PDF

Info

Publication number
AU2019246719B2
AU2019246719B2 AU2019246719A AU2019246719A AU2019246719B2 AU 2019246719 B2 AU2019246719 B2 AU 2019246719B2 AU 2019246719 A AU2019246719 A AU 2019246719A AU 2019246719 A AU2019246719 A AU 2019246719A AU 2019246719 B2 AU2019246719 B2 AU 2019246719B2
Authority
AU
Australia
Prior art keywords
trametinib
dabrafenib
compound
cancer
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019246719A
Other languages
English (en)
Other versions
AU2019246719A1 (en
Inventor
Matthew John MEYER
Youzhen Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2019246719A1 publication Critical patent/AU2019246719A1/en
Application granted granted Critical
Publication of AU2019246719B2 publication Critical patent/AU2019246719B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019246719A 2018-03-30 2019-03-29 A triple pharmaceutical combination comprising dabrafenib, trametinib and an Erk inhibitor Ceased AU2019246719B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650744P 2018-03-30 2018-03-30
US62/650,744 2018-03-30
PCT/IB2019/052601 WO2019186488A1 (en) 2018-03-30 2019-03-29 A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor

Publications (2)

Publication Number Publication Date
AU2019246719A1 AU2019246719A1 (en) 2020-10-01
AU2019246719B2 true AU2019246719B2 (en) 2022-06-16

Family

ID=66397350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019246719A Ceased AU2019246719B2 (en) 2018-03-30 2019-03-29 A triple pharmaceutical combination comprising dabrafenib, trametinib and an Erk inhibitor

Country Status (13)

Country Link
US (1) US20210121460A1 (enExample)
EP (1) EP3773586A1 (enExample)
JP (1) JP2021519285A (enExample)
KR (1) KR20200138303A (enExample)
CN (1) CN111936141A (enExample)
AU (1) AU2019246719B2 (enExample)
BR (1) BR112020019577A2 (enExample)
CA (1) CA3094780A1 (enExample)
CL (1) CL2020002505A1 (enExample)
IL (1) IL277380A (enExample)
MX (1) MX2020010231A (enExample)
RU (1) RU2020135055A (enExample)
WO (1) WO2019186488A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230090389A1 (en) * 2020-02-28 2023-03-23 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
IL295626A (en) * 2020-02-28 2022-10-01 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
KR20240055721A (ko) * 2021-06-24 2024-04-29 아사나 바이오사이언시스 엘엘씨 Erk1/2 억제제 조합 요법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DK3063143T3 (en) * 2013-11-01 2018-08-20 Novartis Ag Amino heteroaryl benzamides as kinase inhibitors
CA2991805A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAOHUA XUE ET AL, "An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer", NATURE MEDICINE, New York, (2017-07-17), vol. 23, no. 8, doi:10.1038/nm.4369, ISSN 1078-8956, pages 929 - 940 *

Also Published As

Publication number Publication date
CA3094780A1 (en) 2019-10-03
CN111936141A (zh) 2020-11-13
BR112020019577A2 (pt) 2021-01-05
IL277380A (en) 2020-11-30
KR20200138303A (ko) 2020-12-09
CL2020002505A1 (es) 2021-03-05
JP2021519285A (ja) 2021-08-10
EP3773586A1 (en) 2021-02-17
AU2019246719A1 (en) 2020-10-01
US20210121460A1 (en) 2021-04-29
MX2020010231A (es) 2020-10-28
WO2019186488A1 (en) 2019-10-03
RU2020135055A (ru) 2022-05-05

Similar Documents

Publication Publication Date Title
WO2022259157A1 (en) A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
US20230090389A1 (en) A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
JP2022520079A (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
US20210121460A1 (en) A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor
US12606616B2 (en) PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
JP7497353B2 (ja) Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法
WO2021171260A2 (en) A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor or a pd-1 inhibitor
HK40121691A (en) Methods for treating cancer resistant to cdk4/6 inhibitors
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired